HC Wainwright Analysts Boost Earnings Estimates for Kamada

Key Points

• HC Wainwright raised Kamada’s earnings forecasts, projecting Q3 2026 EPS of $0.16, up from $0.13, alongside estimates of $0.52 for FY2026 and $1.11 for FY2030.
• Kamada’s latest quarterly results exceeded expectations, with EPS of $0.16 versus the $0.11 consensus and revenue of $54.92 million compared with estimates of $50.84 million.
• Analyst sentiment remains positive, with the stock carrying a consensus “Buy” rating and an average price target of $13.00; institutional investors own 20.38% of shares.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities researchers at HC Wainwright raised their Q3 2026 EPS estimates for shares of Kamada in a research note issued on Friday, August 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.16 for the quarter, up from their prior estimate of $0.13. The consensus estimate for Kamada's current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for Kamada's Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.52 EPS and FY2030 earnings at $1.11 EPS.

Other equities research analysts also recently issued research reports about the stock. Benchmark reiterated a "buy" rating on shares of Kamada in a research note on Tuesday, July 21st. William Blair set a $15.00 price objective on shares of Kamada in a research note on Tuesday, July 21st. Weiss Ratings downgraded shares of Kamada from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, June 25th. Finally, Wall Street Zen upgraded shares of Kamada from a "hold" rating to a "strong-buy" rating in a research report on Saturday. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $13.00.

Kamada Trading Up 2.4%

Shares of NASDAQ:KMDA opened at $7.76 on Tuesday. The firm has a market capitalization of $446.28 million, a PE ratio of 20.42, a PEG ratio of 0.67 and a beta of 0.86. Kamada has a 1-year low of $6.50 and a 1-year high of $9.35. The business's 50 day moving average is $7.23 and its 200-day moving average is $7.95.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The business had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KMDA. Jane Street Group LLC bought a new position in shares of Kamada during the first quarter worth approximately $582,000. Goldman Sachs Group Inc. bought a new position in Kamada during the 1st quarter worth $497,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Kamada during the second quarter worth $472,000. Bank of America Corp DE increased its position in Kamada by 201.0% during the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company's stock worth $427,000 after acquiring an additional 41,111 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Kamada by 25.9% during the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company's stock worth $1,390,000 after purchasing an additional 40,514 shares in the last quarter. Institutional investors and hedge funds own 20.38% of the company's stock.

Kamada Cuts Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th will be given a $0.17 dividend. This represents a dividend yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th. Kamada's dividend payout ratio (DPR) is presently 50.00%.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source